Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Open access
Schoenfeld, A.J., Rizvi, H., Bandlamudi, C., Sauter, J.L., Travis, W.D., Rekhtman, N., Plodkowski, A.J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J.V., Ladanyi, M., Arbour, K.C., Rudin, C.M., Riely, G.J., Taylor, B.S., Donoghue, M.T.A., Hellmann, M.D.·2020·Annals of Oncology

Abstract

Background: PD-L1 expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tumor features on PD-L1 expression is largely unknown and may improve prediction of response to ICI. Methods: We evaluated patients with lung adenocarcinoma in whom PD-L1 testing and targeted next-generation sequencing (MSK-IMPACT) was performed on the same tissue. Clinical and molecular features were compared across PD-L1 subgroups to examine how molecular phenotype associated with tumor PD-L1 expression. In patients treated with anti-PD-(L)1 blockade, we assessed how these interactions impacted efficacy. Results: 1586 patients with lung adenocarcinoma had paired PD-L1 testing and targeted next-generation sequencing. PD-L1 negativity was more common in primary compared to metastatic samples (p <0.001). The distribution of PD-L1 expression (lymph nodes enriched for PD-L1 high; bones predominantly PD-L1 negative) and predictiveness of PD-L1 expression on ICI response varied by organ. Mutations in KRAS, TP53, and MET significantly associated with PD-L1 high expression (each p < 0.001, q < 0.001) and EGFR and STK11 mutations associated with PD-L1 negativity (p <0.001, q = 0.01; p = 0.001, q < 0.001, respectively). WNT pathway alterations also associated with PD-L1 negativity (p = 0.005). EGFR and STK11 mutants abrogated the predictive value of PD-L1 expression on ICI response. Conclusion: PD-L1 expression and association with ICI response varies across tissue sample sites. Specific molecular features are associated with differential expression of PD-L1 and may impact predictive capacity of PD-L1 for response to ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.01.065

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 324

Metadata

Authors
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J. V., Ladanyi, M., Arbour, K. C., Rudin, C. M., Riely, G. J., Taylor, B. S., Donoghue, M. T. A., & Hellmann, M. D.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-05
Volume
31
Issue
5
Pages
599-608
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3005186000
Cited by
324
References
49
FWCI
15.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. https://app.cochat.ai/papers/10.1016/j.annonc.2020.01.065
The paper
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J. V., Ladanyi, M., Arbour, K. C., Rudin, C. M., Riely, G. J., Taylor, B. S., Donoghue, M. T. A., & Hellmann, M. D. (2020). Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.01.065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.